SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding Jupiter's $UPDOG token is highlighting its long-term presence on the Solana network and its placement on the Jupiter Strict List. Active discussions are centered on persistent meme-based engagement, community building, and efforts to drive visibility through ongoing social outreach.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is garnering attention as market participants track its utility within the Base ecosystem, specifically focusing on its role as an infrastructure layer for autonomous AI agents. The community remains actively engaged in discussions regarding the project's potential for scaling, recent ecosystem integrations, and its resilience during broader market fluctuations.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The community is actively debating the legitimacy of the MULN crypto token, with many users drawing parallels to the controversial history of its associated EV company and expressing skepticism about its long-term viability. While some traders attempt to hype the token as a potential high-volatility play, vocal detractors warn of a recurring cycle of manipulation and pump-and-dump tactics often seen in the sector.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is experiencing significant community momentum and trending interest as holders speculate on potential major exchange listings and a broader meme coin rally. Discussions are heavily focused on accumulating positions during price swings and the long-term potential for the token to reduce its circulating supply and erase zeros as market sentiment remains bullish.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

Binance's native token BNB is trending as the community debates its market resilience amid shifting institutional inflows and ongoing regulatory scrutiny. Traders are actively tracking Elliott Wave technical patterns while discussing the exchange's broader role in ecosystem liquidity and decentralized finance.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB is gaining significant momentum on the Base chain, fueled by community narratives surrounding its connection to Grok and AI-driven token mechanics. Investors are actively discussing the potential for major platform listings and a breakout in market capitalization as interest in the AI-meme sector continues to surge.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is experiencing intense community debate as holders push for a breakout to new highs, while skeptics warn of potential rug pulls and declining volume. The community remains highly active, frequently coordinating with other small-cap meme tokens to drive momentum and attract new investors.

Peanut the Squirrel Markets

PNUT is seeing heightened social media activity as traders speculate on potential price action, with many discussing its prospects alongside other popular memecoins. The community is actively debating entry and exit points, frequently highlighting the coin's volatility and the influence of broader crypto market trends on its performance.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls is currently in the spotlight as investors speculate on its potential as a new institutional-grade infrastructure layer following its recent mainnet launch. While some community members are focused on the token burn mechanisms and long-term utility, others are debating whether the recent price volatility presents a buying opportunity or a typical post-launch sell-off.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending due to heightened community optimism surrounding potential on-chain burning mechanisms and speculative anticipation of a major supply shock. Investors remain highly vocal about the project's long-term recovery potential, with active discussions focusing on the impact of staking, validator activity, and the desire for a significant price reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Goldman Sachs Lifts UnitedHealth Target Price: Healthcare ETFs to Watch

Goldman lifts UnitedHealth's target price, spotlighting ETFs like IHF as diversified ways to tap its growth while cushioning Medicaid-driven risks.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Consumer Sentiment Weakens: ETFs That Are Worth a Look

Rising oil prices and Middle East tensions are squeezing household finances and weakening consumer sentiment, steering investors toward defensive ETFs.

Stagflation Scare? ETFs May Help Protect Your Portfolio

Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.

Middle East Turmoil and U.S. Debt Surge: ETFs in Focus

With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.

<ul class="summary-bullets"><li>Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4.</li><li>The company recorded net income of $18 million during the quarter, compared to an $81 million loss during the year-ago period.</li><li>Selling, general, and administrative expenses fell 53% year-over-year.&nbsp;</li></ul>Novavax, Inc. (NVAX) reported a sharp increase in fourth-quarter (Q4) and 2025 revenue as the vaccine maker leaned on partnership income, cost cuts and product sales.The Maryland-based biotech generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. Both the metrics surpassed the analysts’ consensus estimates of $90.26 million and a loss of $0.55, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Q4 Performance Highlights</h2>Annual revenue surged 65% YoY to $1.12 billion, driven in large part by $625 million in Nuvaxovid sales linked primarily to settlements of earlier advance purchase deals.Quarterly product sales totaled $39 million, while full-year product sales rose to $685 million. Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4 and $386 million for the year. The company said it earned $225 million in milestones from the Sanofi collaboration in 2025.<blockquote>"In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&amp;D efforts.”-John C. Jacobs, President and CEO, Novavax</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax stock</a> traded over 1% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;&nbsp;<h2 class="st-heading-2">Costs Fall As Profitability Improves</h2>Novavax reduced its cost of sales to $22 million in the fourth quarter from $37 million a year earlier. The decline followed the divestiture of its Czech manufacturing site and lower overhead and inventory-related charges.Selling, general, and administrative expenses fell more than half YoY as commercial responsibilities transitioned to Sanofi and infrastructure was streamlined. The company recorded net income of $18 million in Q4, compared to an $81 million loss during the year-ago period. Novavax ended 2025 with $751 million in cash and equivalents.&nbsp;NVAX stock has gained ovr 0% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue 

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Equity

<ul class="summary-bullets"><li>PROCEPT BioRobotics’ Q4 revenue of $76.4 million and loss per share of $0.53 both missed street estimates.&nbsp;</li><li>According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%.</li><li>The firm indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.</li></ul>Bank of America has downgraded PROCEPT BioRobotics Corp. (PRCT) shares, citing mounting concerns about earnings visibility and profitability, reflecting skepticism about the company’s near-term performance as it navigates widening losses.In the fourth quarter (Q4), the company reported a revenue of $76.4 million, a 12% year-over-year (YoY) increase, and a loss per share (EPS) of $0.53. Both the financial metrics were below the analysts’ consensus estimates of $93.70 million and a loss of $0.31, respectively, according to Fiscal AI data.&nbsp;<a href="https://stocktwits.com/symbol/PRCT">PROCEPT BioRobotics’ stock</a> traded over 28% lower in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">BofA Flags Profitability Concerns</h2>Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’ and slashed its price target to $20 from $38, according to TheFly. The firm flagged fresh doubts following the company’s Q4 earnings discussion, noting uncertainty about whether management can meet Wall Street’s projections.&nbsp;Bank of America indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%. The shortfall coincides with a shift in the company’s longstanding approach to offering volume-based discounts to customers. At the same time, management has undertaken a reorganization of its sales team, adding another layer of transition risk.The firm emphasized that the company remains unprofitable, with operating losses deepening after the latest earnings. That trend, Bank of America argued, constrains the stock’s valuation and limits potential upside in the near term.&nbsp;<h2 class="st-heading-2">Retail Traders Remain Bullish Despite Selloff</h2>However, on Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume flipped to ‘extremely high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_26_055954_png_4ab610861f.webp" alt="PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits" width="933" height="101"><figcaption>PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits</figcaption></figure>PRCT stock has declined by over 59% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the PROCEPT BioRobotics Corporation logo is seen displayed on a smartphone screen.

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


<ul class="summary-bullets"><li>Geron posted RYTELO net product sales of $48 million in the fourth quarter, and the number of ordering accounts increased to roughly 1,300.</li><li>In December, Geron initiated a workforce reduction affecting about one-third of employees, resulting in $17 million in restructuring charges.</li><li>For 2026, Geron projects RYTELO revenue between $220 million and $240 million.</li></ul>Geron Corp. (GERN) reported fourth-quarter and full-year 2025 results on Wednesday, highlighting rising sales of its blood cancer therapy RYTELO as the company sharpens its focus on expanding adoption in lower-risk myelodysplastic syndromes (LR-MDS).Total revenue reached $48 million in the fourth quarter, with a loss per share (EPS) of $0.05. Both the metrics&nbsp;came&nbsp;in below the analysts’ consensus estimates of $50.88 million and a loss of $0.04, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">RYTELO Sales And Demand Climb</h2>However, Geron posted RYTELO net product sales of $48 million for Q4 and $183.6 million for the full year. Demand rose 9% in the fourth quarter compared with the prior quarter, while the number of ordering accounts increased by 150 to roughly 1,300.The company said it is supporting more than 10 investigator-sponsored and real-world studies examining RYTELO’s mechanism, potential combinations, and earlier-line use. Initial findings from those efforts are anticipated in the second half of 2026.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GERN">Geron's stock</a> traded over 10% lower in Wednesday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Expenses And Outlook&nbsp;</h2>Operating costs for 2025 were $254.7 million. Research and development spending declined, reflecting reduced clinical trial activity after the FDA’s RYTELO approval in 2024. Selling, general, and administrative costs increased due to expanded commercial efforts. In December, Geron initiated a workforce reduction affecting about one-third of employees, resulting in $17 million in restructuring charges.For 2026, Geron projects RYTELO revenue of $220 million to $240 million, with operating expenses of $230 million to $240 million.GERN stock declined by over 17% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rbbn-stock-gains-pre-market-today-what-is-behind-the-rally/cZRyd8HRIGE">RBBN Stock Gains Over 8% Pre-Market Today – What’s Behind The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did GERN Stock Tumble 10% Pre-Market Today? 

Total revenue reached $48 million for the fourth quarter, with a loss per share of $0.05, with both metrics coming in below street estimates. 

<ul class="summary-bullets"><li>The therapy is to treat adults and children with Friedreich’s ataxia, a progressive neurodegenerative disorder.</li><li>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;</li><li>FDA agreed that skin FXN could serve as a novel surrogate endpoint, supporting the planned Biologics License Application submission.</li></ul>Larimar Therapeutics, Inc. (LRMR) announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its frataxin (FXN) protein replacement therapy, nomlabofusp.&nbsp;The therapy is to treat adults and children with Friedreich’s ataxia (FA), a progressive neurodegenerative disorder causing nervous system damage.<h2 class="st-heading-2">FDA Endorses Skin FXN As Surrogate Endpoint</h2>The FDA’s decision follows encouraging clinical data from Larimar’s ongoing open-label study and a recent Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program meeting.&nbsp;The agency also agreed that skin FXN could serve as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting the planned Biologics License Application (BLA) submission targeted for June 2026. The FDA additionally confirmed that the planned analyses, reference population, and clinical endpoints are aligned with BLA requirements.Following the FDA’s decision,&nbsp;<a href="https://stocktwits.com/symbol/LRMR">Larimar stock</a> traded over 30% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_084542_png_18caaedccf.webp" alt="LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Encouraging Clinical Data</h2>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;Improvements were seen across four key clinical measures, the modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (ADL), 9-Hole Peg Test (9-HPT), and Modified Fatigue Impact Scale (MFIS) after one year of treatment.&nbsp;The results suggest that nomlabofusp could slow or reverse FA progression compared with the natural disease course observed in the Friedrich’s Ataxia Clinical Outcomes Measure Study (FACOMS).LRMR stock declined by over 7% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intuit-stock-rallies-pre-market-today-anthropic-connection/cZRvyjtR4C7">Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? 

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

IYH
iShares US Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IYH News

IYHiShares US Healthcare ETF